BMJ23h
Kawasaki disease in infants 3 months of age and younger: a multicentre Spanish study
Correspondence to Dr Elisa Fernandez-Cooke, Department of Pediatrics Infectious Diseases, Doce de Octubre University Hospital, Madrid 28041, Spain; elisafcooke{at}gmail.com Kawasaki disease (KD) is a ...
BMJ1d
FRI0582 Fluctuating Levels of Rheumatoid Factor Predict Progression of Rheumatoid Arthritis, but Not Independent of Disease Activity
Background The presence of rheumatoid factor (RF) is associated with progression of joint damage in patients with rheumatoid arthritis (RA). RF levels may change during the course of therapy 1, but it ...
BMJ2d
POS0449 GENE THERAPY WITH INTERFERENCE miRNAs AS A NEW ALTERNATIVE FOR DISCOID CUTANEOUS LUPUS (DLE)
Background: Discoid Lupus Erythematosus (DLE) represents a chronic and recurrent cutaneous manifestation of Lupus Erythematosus, characterized by a variable course and a pronounced tendency to leave ...
BMJ3d
OP0033 ANALYSIS OF B CELL SUBSETS AND B CELL CYTOKINES IN PEDIATRIC SJOGREN’S SYNDROME
Background Pediatric Sjögren’s syndrome (pSS) is a rare disorder that is often diagnosed late due to the lack of validated diagnostic criteria and validated biomarkers. The pathogenesis is largely ...
BMJ3d
AB1037 CURRENT USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
Background: The current “treat-to-target (T2T)” strategic concept has been applied to systemic lupus erythematosus (SLE), stating “lupus maintenance treatment should aim for the lowest glucocorticoid ...
BMJ3d
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ4d
THU0266 Cgamp and Cgas Are Expressed in A Subset of Patients with Systemic Lupus Erythematosus and Associate with Disease Activity
Background Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) and “interferonopathies” such as Aicardi-Goutieres Syndrome (AGS). A recently ...
BMJ5d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ5d
Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis
Objectives Recent studies indicate that glucose metabolism is altered in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). Hexokinases (HKs) catalyse the first step in glucose metabolism, ...
BMJ5d
AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers
Background Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining a favorable safety profile and clinical efficacy in patients after 4 weeks of dosing with rheumatoid arthritis (RA ...
BMJ5d
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging
Background: Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS). Objectives: To detect differentially the presence ...
BMJ5d
Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...